$CNO

Tarasi Rocco F. III sold $97K of CNO

Tarasi Rocco F. III (Chief Marketing Officer) sold 1,891 shares of CNO Financial Group, Inc. (CNO) at $51.31 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tarasi Rocco F. III
Published Jul 1, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CNO
Neutral
high confidence
Mentioned
$CNO
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CMO under a pre-arranged 10b5-1 plan; it is not a guidance, earnings, or regulatory update.

02

Market read

Traders may treat this as low-signal information; it mainly updates the insider activity record for CNO.

03

What to watch

The article provides only the sale details; it does not state whether other insiders bought, whether there were concurrent corporate events, or whether the plan size/timing is unusual.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-01 (after-hours) for an insider sale dated 2026-07-01.

Background

The article is an SEC Form 4 insider transaction for CNO Financial Group, filed on 2026-07-01.

Company-level read

Ticker impact

$CNONeutralHigh confidence
Context

CNO Financial Group insider Tarasi Rocco F. III sold 1,891 shares on 2026-07-01 at $51.31 via a 10b5-1 plan, per Form 4.

Expected impact

Minimal near-term impact; any effect is likely noise unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory catalyst in the text.

Market effects

No sector read-across; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with private concerns; traders may still monitor for follow-on insider buys or changes in sale patterns.

Key entities

  • CNO Financial Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tarasi Rocco F. III

    Chief Marketing Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNOMed

California Nanotechnologies Posts 28% Revenue Growth in Q1 FY2027 as Nuclear Pivot Takes Hold

California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.

$CNOHighAI 9/10

CNO Financial (CNO) Q2 2026 Earnings Call Transcript

CNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.

$CNOMed

CNO Financial posts insurance income gain on 16-quarter sales streak

CNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.

$CNOMed

CNO Financial Group’s (NYSE:CNO) Q2 CY2026 Sales Beat Estimates

Insurance services company CNO Financial Group (NYSE: CNO) announced better-than-expected revenue in Q2 CY2026, with sales up 34.6% year on year to $1.29 billion. Its GAAP profit of $1.33 per share was 36.4% above analysts’ consensus estimates. Is now the time to buy CNO Financial Group? Find out by accessing our full research report, it’s free.

$CNOLow

CNO Financial Group, Inc. (CNO): Results of Operations and Financial Condition

CNO Financial Group, Inc. (CNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. News For Immediate Release CNO Financial Group Reports Second Quarter 2026 Results Carmel, Ind., July 30, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results: • Strong execution and momentum continues; Raising 2026 operating earni